Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BA3021 + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BA3021||CAB-ROR2-ADC|BA 3021|Ozuriftamab Vedotin||BA3021 (CAB-ROR2-ADC) is a conditionally active anti-ROR2 antibody in conjugation with a cytotoxic agent that preferentially binds and delivers cytotoxicity to Ror2-expressing cells in tumors, which potentially induces antitumor activity (Cancer Res (2018) 78 (13_Supplement): 833).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04918186||Phase II||BA3021 + Durvalumab Durvalumab + Mecbotamab Vedotin||Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)||Recruiting||USA | CAN||0|